Page 144 - Haematologica April 2020

H. Kumar et al.
Redox Signal. 2012;16(11):1215-1228.
28. Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem. 2002;383(3-
4):347-364.
29. Ma Q. Role of nrf2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol.
2013;53:401-426.
30. Kim JH, Bogner PN, Baek SH, et al. Up-reg-
ulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeu- tic target. Clin Cancer Res. 2008;14(8):2326- 2333.
31. Tanno B, Sesti F, Cesi V, et al. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. 2010;285(38):29434-29445.
32. Wang QF, Lauring J, Schlissel MS. c-Myb binds to a sequence in the proximal region of the RAG-2 promoter and is essential for promoter activity in T-lineage cells. Mol Cell Biol. 2000;20(24):9203-9211.
33. Deng QL, Ishii S, Sarai A. Binding site analy- sis of c-Myb: screening of potential binding sites by using the mutation matrix derived from systematic binding affinity measure- ments. Nucleic Acids Res. 1996;24(4):766- 774.
34. Suhasini M, Pilz RB. Transcriptional elonga- tion of c-myb is regulated by NF-kappaB (p50/RelB). Oncogene. 1999;18(51):7360- 7369.
35. Pereira LA, Hugo HJ, Malaterre J, et al. MYB elongation is regulated by the nucleic acid binding of NFκB p50 to the intronic stem- loop region. PLoS One. 2015;10(4): e0122919.
36. Toth CR, Hostutler RF, Baldwin AS, Jr., Bender TP. Members of the nuclear factor kappa B family transactivate the murine c- myb gene. J Biol Chem. 1995;270(13):7661- 7671.
37. Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is required for PKB-mediated pro- tection from apoptosis. Mol Cell Biol. 2001;21(17):5797-5805.
38. Campanero MR, Armstrong M, Flemington E. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol Cell Biol. 1999;19(12):8442-8450.
39. Kim MY, Koh DI, Choi WI, et al. ZBTB2 increases PDK4 expression by transcription- al repression of RelA/p65. Nucleic Acids Res. 2015;43(3):1609-1625.
40. Xu H, You M, Shi H, Hou Y. Ubiquitin- mediated NFκB degradation pathway. Cell Mol Immunol. 2015;12(6):653-655.
41. Hou Y, Moreau F, Chadee K. PPARγ is an E3
ligase that induces the degradation of
NFκB/p65. Nat Commun. 2012;3:1300.
42. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci.
2004;24(48):10908-10917.
43. Aprile M, Cataldi S, Ambrosio MR, et al.
PPARγδ5, a naturally occurring dominant- negative splice isoform, impairs PPARγ func- tion and adipocyte differentiation. Cell Rep. 2018;25(6):1577-1592 e1576.
44. Liu JJ, Huang RW, Lin DJ, et al. Expression of survivin and bax/bcl-2 in peroxisome prolif- erator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol. 2005;16(3):455-459.
45. Bitencourt R, Zalcberg I, Louro ID. Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2011;33(6):470-475.
46. Sauri H, Ashjian PH, Kim AT, Shau H. Recombinant natural killer enhancing factor augments natural killer cytotoxicity. J Leukoc Biol. 1996;59(6):925-931.
47. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424(6948):561- 565.
48. Cao J, Schulte J, Knight A, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 2009;28(10): 1505-1517.
49. Ding C, Fan X, Wu G. Peroxiredoxin 1 - an antioxidant enzyme in cancer. J Cell Mol Med. 2017;21(1):193-202.
50. Mascarenhas C, Woldmar L, Almeida MH, Andrade RV, Cunha AF, De Souza CA. Evaluation of peroxiredoxins (PRDX1, PRDX2 and PRDX6) expression in patients with chronic myeloid leukemia (CML) treat- ed with imatinib in first line. Blood. 2014;124(21):5545-5545.
51. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progeni- tors. Blood. 2012;119(18):4253-4263.
52. Riddell JR, Wang XY, Minderman H, Gollnick SO. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol. 2010;184 (2):1022-1030.
53. Liu CH, Kuo SW, Hsu LM, et al. Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating
extracorporeal membrane oxygenation: an observational cohort study and translational approach. J Transl Med. 2016;14(1):114.
54. Ratajczak MZ, Perrotti D, Melotti P, et al. Myb and ets proteins are candidate regula- tors of c-kit expression in human hematopoietic cells. Blood. 1998;91(6):1934- 1946.
55. Melotti P, Ku DH, Calabretta B. Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb. J Exp Med. 1994;179(3):1023-1028.
56. Volpe G, Walton DS, Del Pozzo W, et al. C/EBPα and MYB regulate FLT3 expression in AML. Leukemia. 2013;27(7):1487-1496.
57. Lutwyche JK, Keough RA, Hughes TP, Gonda TJ. Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. Br J Haematol. 2001;114(3):632-634.
58. Bussolari R, Candini O, Colomer D, et al. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. Leuk Res. 2007;31(2):163-167.
59. Ratajczak MZ, Hijiya N, Catani L, et al. Acute- and chronic-phase chronic myeloge- nous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynu- cleotides. Blood. 1992;79(8):1956-1961.
60. Calabretta B, Sims RB, Valtieri M, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynu- cleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci U S A. 1991;88(6):2351-2355.
61. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of BCR-ABL1-mediated NF-kappaB/Rel acti- vation. Exp Hematol. 2003;31(6):504-511.
62. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myel- ogenous leukemia cells. Blood. 2001;98(8): 2301-2307.
63. Lounnas N, Frelin C, Gonthier N, et al. NF- kappaB inhibition triggers death of ima- tinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I BCR-ABL1 mutants. Int J Cancer. 2009;125(2):308-317.
64. LuZ,JinY,ChenC,LiJ,CaoQ,PanJ. Pristimerin induces apoptosis in imatinib- resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting BCR- ABL1. Mol Cancer. 2010;9:112.
986
haematologica | 2020; 105(4)